RETA - Reata Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
72.00
+1.45 (+2.06%)
As of 12:40PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close70.55
Open70.70
Bid71.97 x 1200
Ask72.36 x 800
Day's Range69.06 - 72.46
52 Week Range19.31 - 85.39
Volume112,096
Avg. Volume402,537
Market Cap2.137B
Beta2.52
PE Ratio (TTM)N/A
EPS (TTM)-1.47
Earnings DateAug 9, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est112.33
Trade prices are not sourced from all markets
  • Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimates
    Zacks9 days ago

    Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimates

    Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -40.54% and -16.89%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire9 days ago

    Reata Pharmaceuticals, Inc. Announces Second Quarter 2018 Financial Results and an Update on Development Programs

    IRVING, Texas, Aug. 08, 2018-- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today provided an update on the Company's product development programs and announced financial results ...

  • GlobeNewswire11 days ago

    Reata Pharmaceuticals, Inc. to Report Second Quarter 2018 Financial Results and an Update on Development Programs on Wednesday, August 8, 2018

    IRVING, Texas, Aug. 06, 2018-- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and live webcast on Wednesday, August ...

  • 3 Healthcare Stocks That Skyrocketed 35% or More This Week: Are They Still Buys?
    Motley Fool20 days ago

    3 Healthcare Stocks That Skyrocketed 35% or More This Week: Are They Still Buys?

    These stocks jumped much higher over the last few days. But should investors jump on the bandwagon?

  • GlobeNewswire21 days ago

    Reata Pharmaceuticals, Inc. Announces Closing of Class A Common Stock Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 3,450,000 shares of its Class A common stock, which included 450,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $72.00 per share.  The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $248.4 million. Reata intends to use the net proceeds from the offering for working capital and general corporate purposes, which include, but are not limited to, advancing the development of bardoxolone methyl and omaveloxolone through clinical trials, preparing to file one or more New Drug Applications, and planning for commercialization of its potential products.

  • GlobeNewswire23 days ago

    Investor Expectations to Drive Momentum within Reata Pharmaceuticals, Shoe Carnival, United Fire Group, Approach Resources, Saul Centers, and Tennant — Discovering Underlying Factors of Influence

    NEW YORK, July 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Reata ...

  • GlobeNewswire24 days ago

    Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Public Offering

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 3,000,000 shares of its Class A common stock at a price to the public of $72.00 per share.  The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $216,000,000.  In addition, Reata has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of Reata’s Class A common stock on the same terms and conditions.  The offering is expected to close on July 27, 2018, subject to customary closing conditions. Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering.  Ladenburg Thalmann & Co. Inc. is acting as co-manager for the offering.

  • ACCESSWIRE24 days ago

    These Biotech Stocks Should Be On Your Watch-List

    CORAL GABLES, FL / ACCESSWIRE / July 24, 2018 / The Nasdaq Biotechnology Index (IBB) just made a new 52-week high today and most likely an all-time high may not be out of the question either. As most of the market shutters about the trade wars, biotech stocks are more insulated from the biggest concern about tariffs compared to most industries. Biotech companies like GT Biopharma, Inc. (GTBP), Reata Pharmaceuticals (NASDAQ: RETA) and Biogen (NASDAQ: BIIB) have all released news within the last 10 days that has sparked much more interest in the market for these stocks.

  • ACCESSWIRE24 days ago

    Today’s Research Reports on Stocks to Watch: Reata Pharmaceuticals and LifePoint Health

    NEW YORK, NY / ACCESSWIRE / July 24, 2018 / Both Reata Pharmaceuticals and LifePoint were trading significantly higher on strong trading volume after Wall Street learned about positive developments from ...

  • Here's Why Reata Pharmaceuticals Skyrocketed 65% Today
    Motley Fool25 days ago

    Here's Why Reata Pharmaceuticals Skyrocketed 65% Today

    A drug targeting a rare form of chronic kidney disease is fueling investor's optimism.

  • GlobeNewswire25 days ago

    Reata Pharmaceuticals, Inc. Announces Proposed Public Offering of Class A Common Stock

    Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell 3,000,000 shares of its Class A common stock in an underwritten public offering pursuant to an existing shelf registration statement. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Jefferies LLC, Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering.

  • Why Reata Pharmaceuticals’ Stock Price Is Skyrocketing Today
    Market Realist25 days ago

    Why Reata Pharmaceuticals’ Stock Price Is Skyrocketing Today

    Today, Reata Pharmaceuticals is trading at a stock price of $75.00, which represents a ~61.67% hike from yesterday’s close of $46.4. On July 20, Reata Pharmaceuticals closed at $46.4, which represents ~140% growth from its 52-week low of $19.31 on March 29. Also today, Reata Pharmaceuticals hit a 52-week high of $76.25.

  • GlobeNewswire25 days ago

    Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in CKD Caused by Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced results from two Phase 2 studies of bardoxolone methyl (bardoxolone) in patients with chronic kidney disease (CKD).  Reata reported positive one-year results for the Phase 2 portion of CARDINAL, a study of bardoxolone in patients with CKD due to Alport syndrome, and positive final results for the Phase 2 autosomal dominant polycystic kidney disease (ADPKD) cohort of PHOENIX. In the Phase 2 portion of CARDINAL, significantly increased estimated glomerular filtration rate (eGFR) at Week 48 from baseline (n=25) of 10.4 mL/min/1.73 m2 (p

  • Can The Uptrend Continue for Reata Pharmaceuticals (RETA)?
    Zackslast month

    Can The Uptrend Continue for Reata Pharmaceuticals (RETA)?

    Investors certainly have to be happy with Reata Pharmaceuticals, Inc. (RETA) and its short term performance.

  • GlobeNewswirelast month

    Reata Receives Orphan Drug Designation from the European Commission for Omaveloxolone for the Treatment of Friedreich’s Ataxia

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that the European Commission has granted orphan drug designation for omaveloxolone for the treatment of Friedreich’s ataxia (FA), based on the positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA). Last year, Reata reported results from part 1 of MOXIe, a two-part, international, multi-center, randomized, double-blind, placebo-controlled Phase 2 trial studying the safety and efficacy of omaveloxolone in patients with FA.  Treatment of FA patients with omaveloxolone produced dose- and time-dependent improvements in their modified Friedreich’s Ataxia Rating Scale (mFARS) scores, which are a measure of the neurologic function of FA patients.  Reata is currently enrolling approximately 100 FA patients in the registrational part 2 portion of MOXIe and expects to have results in the second half of 2019.

  • GlobeNewswire2 months ago

    Reata Announces Initiation of a Phase 1 Trial of RTA 1701, a Selective, Oral Allosteric Inhibitor of RORγt

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1 clinical trial of Reata’s RTA 1701, a highly selective and orally bioavailable allosteric RORγt inhibitor.  This Phase 1, first-in-human study is evaluating the safety and pharmacokinetics of RTA 1701 in healthy volunteers and assessing ex vivo suppression of IL-17A secretion.  Initial results are expected in the first half of 2019.

  • GlobeNewswire2 months ago

    Reata Pharmaceuticals, Inc. Secures $125 Million Term Loan Facility

    Reata Pharmaceuticals, Inc. (RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced that it entered into an amended and restated loan and security agreement with Oxford Finance LLC and Silicon Valley Bank, which increased the Company’s term loan facility from $45 million to $125 million.  Proceeds from the loan will be utilized primarily to support Reata’s multiple Phase 2 and 3 clinical trial programs for bardoxolone methyl and omaveloxolone.

  • GlobeNewswire2 months ago

    Reata Announces That Kyowa Hakko Kirin Initiated Ayame, a Phase 3 Trial of Bardoxolone Methyl for the Treatment of Diabetic Kidney Disease

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that its licensee, Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), has initiated a Phase 3 clinical study, AYAME, to assess the efficacy and safety of bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease in Japan. AYAME is a multi-center, randomized, double-blind, placebo-controlled Phase 3 trial enrolling an estimated 700 diabetic kidney disease patients with CKD stage G3 or G4.  The primary efficacy endpoint is time to onset of a ≥ 30% decrease in estimated glomerular filtration rate (eGFR) from baseline or end-stage renal disease (ESRD).  Secondary endpoints include time to onset of a ≥ 40% or ≥ 53% decrease in eGFR from baseline or ESRD, time to onset of ESRD, and change from baseline in eGFR at each evaluation time point.  The estimated study completion date is March 2022.

  • GlobeNewswire3 months ago

    Reata Selected to Present Early-Stage Programs at the BIO International Convention

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that Chief Development Officer, Keith Ward, Ph.D., will present at the Annual BIO International Convention on Wednesday, June 6, 2018, at 1:00 p.m. ET in Boston, MA.  The BIO International Convention is a premier partnering-focused event for the biopharmaceutical industry, and Reata’s selection as a presenting company highlights the strength of its early-stage assets, including RTA 901 and RTA 1701. RTA 901 is a highly potent and selective C-terminal inhibitor of Hsp90, which has a critical role in mitochondrial function, protein folding, and inflammation.  RTA 901 demonstrates profound efficacy in a wide range of animal models of neurologic disease, including diabetic neuropathy and demyelinating nerve injury.  RTA 901 has been evaluated in a Phase 1 clinical trial in healthy volunteers, with no safety or tolerability issues and with an acceptable pharmacokinetic profile.

  • Benzinga3 months ago

    Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 31) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) (Piper Jaffray initiated ...

  • GlobeNewswire3 months ago

    Reata Announces Orphan Drug Designation From the European Commission for Bardoxolone Methyl for the Treatment of Alport Syndrome

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that the European Commission (EC) has granted orphan drug designation, based on the positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), for bardoxolone methyl (bardoxolone) for the treatment of Alport syndrome.

  • ACCESSWIRE3 months ago

    Wired News - Reata Pharma Presented Encouraging Interim Data from PHOENIX Trial Assessing Bardoxolone Methyl in Patients with ADPKD and IgA Nephropathy

    LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Reata Pharmaceuticals, Inc. (NASDAQ: RETA), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RETA as the Company's latest news hit the wire. On May 25, 2018, the Company announced that it has presented results from the ongoing, open-label, Phase-2 PHOENIX trial assessing bardoxolone methyl (bardoxolone) in patients with autosomal dominant polycystic kidney disease (ADPKD) and IgA nephropathy cohorts at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) meeting in Copenhagen.

  • GlobeNewswire3 months ago

    Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study

    Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that positive interim data from the autosomal dominant polycystic kidney disease (ADPKD) and IgA nephropathy cohorts of the ongoing, open-label, Phase 2 PHOENIX trial are being presented by Pablo E. Pergola, M.D., Ph.D., Research Director, Renal Associates, PA, San Antonio, at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) meeting in Copenhagen.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of RETA earnings conference call or presentation 9-May-18 12:00pm GMT

    Q1 2018 Reata Pharmaceuticals Inc Earnings Call and Discussion of Development Programs